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Alzheimer's disease (AD) is a globally prevalent debilitating neurodegenerative disorder with significant socioeconomic implications. Presently, successful neuroprotective or curative treatments for AD are lacking [1] . However, one promising alternative therapy is repetitive Transcranial Magnetic Stimulation (rTMS) [2] . Most studies have chosen the dorsolateral prefrontal cortex (DLPFC) as the stimulus target because of its neuroplasticity and important role in cognitive functions (such as association memory) [3] . Moreover, application of excitatory stimuli to either the left or both DLPFC demonstrated improvements in general cognitive performance and multi-domain cognition [4] . Intermittent theta burst stimulation (iTBS) is a novel, optimized stimulation paradigm which enables increased cortical excitability more rapidly than conventional rTMS [5] . However, no study has previously reported the use of this protocol to improve the clinical symptoms of patients with AD.
The primary aim of this open-label trial was to investigate the clinical efficacy of optimized iTBS in patients with AD. We assessed the efficacy of iTBS protocol to improve association memory (AM), general and multi-domain cognitions, daily functional and neuropsychiatric symptoms, and explored the underlying mechanisms using resting-state functional connectivity (RSFC) analysis. We predicted that a 2-week intervention with iTBS (total 14 sessions) that stimulates the DLPFC would be sufficient to improve the clinical symptoms of AD.
Participants with AD were recruited according to predefined inclusion and exclusion criteria (details provided in the supplementary material) from the memory clinic of the First Affiliated Hospital of Anhui Medical University, China, and underwent a standardized evaluation. The study was approved by the Research Ethics Committee of Anhui Medical University. All subjects provided written informed consent and the study was conducted in accordance with the Declaration of Helsinki.
In this study, participants received 14 treatment sessions daily over a two-week period. A MagStim Rapid 2 stimulator (MagStim Company Ltd.) with a 70-mm air-cooled figure-of-eight coil was used to deliver the iTBS treatment [5] . All stimulations were guided by participants' anatomical image (1 × 1 × 1 mm 3 ) and a frameless neuro-navigation system (Brainsight; Rogue Research, Montreal, QC, 3 Canada). The stimulation was delivered on the left DLPFC proper using Montreal Neurological Institute (MNI) coordinates (−38, 44, 26) with an intensity equivalent to 70% of the resting motor threshold. A total of 1800 pulse stimulations were delivered 3 times daily in 600-pulse increments with two 15-minute breaks between sessions.
Participants underwent a complete neuropsychological battery of tests (see details in the supplementary materials) as well as a multimodal magnetic resonance imaging (MRI) scanning before the iTBS treatment (pre-treatment) and one day after the last stimulation session (post-treatment).
Four men and nine women with AD were enrolled to receive the treatment. The MRI images of two patients were excluded from analysis because of excessive head-motion artifacts. The treatment was well-tolerated and no severe adverse events were reported (2 patients reported painful scalp sensations, which disappeared after completion of the stimulation).
iTBS induced significant improvement in AM both in free recall (from 0.81 ± 1.47 at pre-treatment to 2.00 ± 2.18 at post-treatment; t = −3.19; p = 0.008) and in recognition (from 4.42 ± 2.65 at pre-treatment to 6.35 ± 2.81 at post-treatment; t = −5.67; p< 0.001). Cognitive enhancement also was found in memory, attention, executive, and language functions ( Fig. 1 A-C) . Furthermore, the behavioral and psychiatric symptoms ameliorated with treatment. The DLPFC is involved in memory retrieval functions during free recall and its hypoactivity has been suggested to be a key substrate of behavioral and psychiatric symptoms in AD [6] . iTBS, as an excitatory protocol, may increase the activity of DLPFC and facilitate improvement in memory. Robust synaptic plasticity is critical for cognitive processes, such as learning and memory [7] . Liao Moreover, RSFC of seed-to-whole-brain analysis revealed that the connection between the target and right precuneus cortex (voxel = 79; peak MNI coordinate, 9, 4 −72, 51) showed a dramatic decrease after treatment (RSFC change [post-pre], −0.2 ± 0.08; t = 8.77; p < 0.05; Fig. 1 E) . The change correlated significantly with improvement in the verbal fluency test-semantic (r = −0.694; p = 0.018; Fig. 1 D) .
iTBS to the left DLPFC may enhance both its cortical excitability and function.
Moreover, the abnormally elevated connectivity between the DLPFC and precuneus may ameliorate after iTBS [9] . This change has also been reported by previous rTMS studies [10] . This pilot study provides direct evidence that iTBS of the left DLPFC improves association memory as well as the clinical symptoms and cognitive performance of patients with AD. We also observed a negative correlation between improvement in cognitive function and connectivity of the DLPFC and right precuneus. Finally, our study showed that iTBS is well-tolerated in patients with AD. These results provide the first evidence for the potential utility of iTBS to improve cognitive function in patients with AD.
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